Core Viewpoint - Zai Ding Pharma (ZLAB) has shown a positive market performance with a 2.1% increase in stock price, reaching $34.205 per share, and a total market capitalization of $3.823 billion as of August 21 [1] Financial Performance - As of June 30, 2025, Zai Ding Pharma reported total revenue of $216 million, reflecting a year-on-year growth of 15.35% [1] - The company recorded a net loss attributable to shareholders of $89.165 million, which represents a year-on-year increase of 33.33% [1] Company Overview - Zai Ding Pharma is a patient-centric, innovative global biopharmaceutical company that is in the commercialization stage, focusing on providing optimal and first-in-class drugs for oncology, autoimmune diseases, infectious diseases, and central nervous system disorders [1] - The company's mission is to become a leading global biopharmaceutical company, delivering transformative innovative drugs to patients in China and worldwide [1] - Zai Ding Pharma aims to establish itself as a global leader in biopharmaceuticals, leveraging its base in China to provide innovative therapies for patients globally [1]

Group 1 - The stock price of Zai Lab (ZLAB) opened at $34.85 per share, up 2.26%, with a total market capitalization of $3.832 billion as of August 8 [1] - For the fiscal year ending March 31, 2025, Zai Lab reported total revenue of $106 million, representing a year-over-year growth of 22.19%, while the net profit attributable to shareholders was -$48.438 million, showing a year-over-year increase of 9.41% [1] Group 2 - Zai Lab is a patient-centered, innovative global biopharmaceutical company that is in the commercialization stage, focusing on providing optimal and first-in-class drugs for oncology, autoimmune diseases, infectious diseases, and central nervous system disorders [2] - The company's mission is to become a leading global biopharmaceutical company, offering transformative innovative drugs to patients in China and around the world [2] - Zai Lab's long-term goal is to establish itself as a global leader in biopharmaceuticals, leveraging its base in China to provide innovative therapies for patients worldwide [2]